Mini-allografts: Ongoing trials in humans

Bone Marrow Transplantation

Volumn 25, Issue 4, 2000, Pages 345-350

  Carella, A M ^a   Champlin, R ^b   Slavin, S ^c   McSweeney, P ^d   Storb, R ^d  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d USA   (United States)

Author keywords

Allografting; Graft versus tumor; Nonmyeloablative regimens

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

AGE; ALLOGRAFT; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CLINICAL TRIAL; EDITORIAL; GRAFT REJECTION; GRAFT VERSUS LEUKEMIA EFFECT; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE; LYMPHOCYTE TRANSFUSION; MAJOR CLINICAL STUDY; META ANALYSIS; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENCE RISK; SAFETY; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION;

EID: 0033996949     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702204     Document Type: Editorial

References (42)

1. Thomas ED. The role of bone marrow transplantation for eradication of malignant disease. Cancer 1969; 10: 1963-1969.
2. Thomas ED. Bone marrow transplantation for malignant disease. J Clin Oncol 1983; 1: 517-531.
3. Rondòn G, Giralt S, Huh Y et al. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1996; 18: 669-672.
4. Van Besien K, Sobocinski K, Rowlings PA et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998; 92: 1832-1836.
5. Khouri IF, Przepiorka D, Van Besien K et al. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol 1997; 97: 466-473.
6. Tricot G, Vesole DH, Jagannath S et al. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196-1198.
7. Ueno NT, Rondòn G, Mirza NQ et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 1998; 16: 986-993.
8. Eibl B, Schwaighofer H, Nachbaur D et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501-1508.
9. Childs RW, Clave E, Tisdale J et al. Successful treatment of metastatic renal cell carcinoma with a non-myeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol 1999; 17: 2044-2050.
10. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995; 23: 1553-1562.
11. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204.
12. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
13. Porter DL, Roth MS, McGarigle C et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. New Engl J Med 1994; 330: 100-106.
14. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
15. Mackinnon S, Papadopoulos EB, Carabassi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-1268.
16. Giralt S, Hester J, Huh Y et al. CD8-depleted donor lymphocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995; 86: 4337-4343.
17. Giralt S, Gajewski J, Khouri I et al. Induction of graft-versus-leukemia as primary treatment of chronic myelogenous leukemia. Blood 1997; 90: 3204-3213.
18. Collins RH Jr, Shpilberg O, Drobyski WR et al. Donor lymphocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
19. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-2968.
20. Storb R, Yu C, Barnett T et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given lymph node irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1999; 90: 1131-1136.
21. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997: 89: 4531-4536.
22. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
23. Keating MJ, Kantarjian H, Talpaz M et al. Fludarabine a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19-25.
24. Storb R. Nonmyeloablative preparative regimens: experimental data and clinical practice. ASCO: 1999 Educational Book, p 241, 55th Annual Meeting, May 15-18, Atlanta.
25. Giralt S, Gajewski J, Khouri I et al. Induction of graft-versus-leukemia as primary treatment of chronic myelogenous leukemia. Blood 1997; 90 (Suppl.1): 1857a.
26. Giralt S, Cohen A, Mehra R et al. Preliminary results of fludarabine/melphalan or 2CDA/melphalan as preparative regimens for allogeneic progenitor cell transplantation in poor candidates for conventional myeloablative conditioning. Blood 1997; 90 (Suppl.1): 1853a.
27. Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
28. Childs R, Clave E, Contentin N et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234-3241.
29. Sykes M, Preffer F, McAfee S et al. Mixed lymphohematopoietic chimerism and graft versus lymphoma effect are achievable in adult recipients following non-myeloablative therapy and HLA-mismatched donor bone marrow transplantation. Lancet 1999; 353: 1755-1759
30. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
31. Nagler A, Or R, Naparstek E et al. Matched unrelated bone marrow transplantation (BMT) using a non-myeloablative conditioning regimen. Blood 1998; 92 (Suppl. 1): 289a (Abstr. 1185).
32. Nagler A, Or R, Naparstek E et al. Secondary allogeneic stem cell transplantation (alloSCT) using a non-myeloablative conditioning regimen for patients with hematological malignancies. Blood 1998; 92 (Suppl. 1): 137a (Abst. 553).
33. Wagner JL, Storb R. Preclinical large animal models for hematopoietic stem cell transplantation. Curr Opin Hematol 1996; 3: 410-416.
34. Storb R, Raff RF, Graham T et al. Marrow toxicity of fractionated versus single dose total body irradiation is identical in a canine model. Int J Radiat Oncol Biol Phys 1993; 26: 275-281.
35. Storb R, Raff RF, Appelbaum FR et al. Comparison of fractionated to single-dose total body irradiation in conditioning canine littermates for DLA-identical marrow grafts. Blood 1989; 74: 1139-1143.
36. Yu C, Storb R, Mathey B et al. DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment. Blood 1995; 86: 4376-4381.
37. Storb R, Yu C, Wagner JL et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048-3054.
38. Storb R, Yu C, Zaucha JM et al. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy TBI before and pharmacological immunosuppression after marrow transplant. Blood 1999; 94: 2523-2529.
39. Woolfrey AE, Nash RA, Frangoul HA et al. Non-myeloablative transplant regimen used for induction of multi-lineage allogeneic hematopoietic mixed donor-host chimerism in patients with T-cell immunodeficiency. Blood 1998; 92 (Suppl. 1): 520a (Abstr. 2135).
40. McSweeney PA, Storb R. Mixed chimerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant 1999; 5: 192-203.
41. Carella AM, Lerma E, Dejana A et al. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias. Haematologica 1998; 83: 904-909.
42. Carella AM, Lerma E, Corsetti MT et al. Evidence of cytogenetic and molecular remission by allogeneic cells after immunosuppressive therapy alone. Br J Haematol 1998; 103: 565-567.